Semax: The Complete Guide to the Cognitive Performance Peptide

If anxiety is the shadow, Semax is the light — not by dulling your senses or slowing your thoughts, but by sharpening them. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s, Semax is a synthetic neuropeptide with a remarkable profile: it enhances focus, memory, and cognitive endurance while simultaneously protecting the brain from stress, injury, and neurodegeneration.

Unlike stimulants that borrow from tomorrow's reserves, Semax appears to build neural infrastructure — upregulating growth factors, modulating neurotransmitter systems, and strengthening the very biological machinery of thought. It has been used clinically in Russia for decades, approved for conditions ranging from ischemic stroke to cognitive dysfunction, and is now attracting serious interest from the Western nootropics and peptide research communities.

This guide covers Semax in depth: its mechanism of action, clinical evidence, dosing protocols, variants (including N-Acetyl Semax Amidate), comparison with Selank, and its safety profile.

What Is Semax?

Semax is a synthetic heptapeptide analog of the adrenocorticotropic hormone (ACTH) fragment ACTH(4-7), extended with a Pro-Gly-Pro (PGP) tripeptide to increase metabolic stability. Its amino acid sequence is Met-Glu-His-Phe-Pro-Gly-Pro.

Critically, despite being derived from ACTH, Semax carries no hormonal activity — it does not stimulate the adrenal glands or raise cortisol. Instead, the ACTH fragment in Semax is responsible solely for its neurological and nootropic effects, while the PGP tail protects it from rapid enzymatic degradation in the nasal mucosa and bloodstream.

In Russia, Semax is registered as a pharmaceutical and has been clinically approved for:

• Ischemic stroke and transient ischemic attack (TIA)
• Perinatal brain hypoxia
• Cognitive disorders and neurasthenia
• Optic nerve disease
• Peptic ulcer (gastrointestinal use)

This breadth of approved indications reflects decades of institutional confidence in Semax's safety and efficacy — a distinction that few research peptides can claim.

How Semax Works: Mechanism of Action

Semax's mechanisms are multi-layered, touching neurotrophic signaling, neurotransmitter regulation, and neuroprotective pathways simultaneously.

BDNF and TrkB Upregulation

The most studied and impactful mechanism of Semax is its ability to rapidly and robustly elevate brain-derived neurotrophic factor (BDNF) in the hippocampus.

A landmark study published in Brain Research (Dolotov et al., 2006) found that a single administration of Semax (50 μg/kg) produced:

• A 1.4-fold increase in hippocampal BDNF protein levels
• A 3-fold increase in BDNF mRNA (exon III)
• A 2-fold increase in TrkB mRNA — the receptor through which BDNF signals
• A 1.6-fold increase in TrkB tyrosine phosphorylation, indicating activated BDNF signaling

BDNF is fundamental to long-term potentiation (LTP) — the process of synaptic strengthening that underlies learning and memory. Its upregulation is associated with improved memory consolidation, faster learning, and protection against neurodegenerative processes. Low BDNF is implicated in depression, anxiety, cognitive decline, Alzheimer's disease, and PTSD.

NGF and Neurotrophic Cascade

In addition to BDNF, Semax elevates nerve growth factor (NGF) — another critical neurotrophic protein supporting the survival and growth of neurons, particularly in the cholinergic system which governs memory and attention. This dual upregulation of neurotrophic factors helps explain Semax's broad neuroprotective profile.

Monoamine Neurotransmitter Modulation

Semax interacts with multiple neurotransmitter systems:

• Dopaminergic: Enhances dopamine release and receptor sensitivity, contributing to improved motivation, focus, and reward processing
• Serotonergic: Modulates serotonin activity, contributing to mood stabilization and reduced stress reactivity
• Cholinergic: Supports acetylcholine activity in memory-critical brain regions
• Enkephalinergic: Influences endorphin and enkephalin systems, modulating pain perception and emotional tone

This multi-neurotransmitter engagement is unusual for a single compound and helps explain the breadth of reported effects — from improved focus to reduced anxiety to better emotional resilience.

Gene Expression and Neuroprotection

Semax modulates the expression of hundreds of genes involved in neuronal survival, synaptic plasticity, and immune response in the brain. In stroke models, Semax's gene expression effects shift the post-ischemic cascade toward neuroprotection: reducing inflammatory cytokines, supporting vascular repair, and promoting survival of neurons in the penumbra (the vulnerable zone around the infarct core).

Research and Clinical Evidence

Cognitive Enhancement

Semax has demonstrated nootropic effects across multiple animal and human studies:

• Improved learning and memory consolidation in rodent models
• Enhanced attention and information processing speed in human subjects
• Better performance under stress conditions, where cognition typically degrades
• Restoration of behavioral and cognitive function in Alzheimer's disease mouse models (APP/PS1 mice), including improved performance in Barnes maze tests to levels comparable with wild-type controls (2025 study, PMC)

Stroke and Neuroprotection

One of the most compelling bodies of evidence concerns Semax's role in ischemic stroke recovery. In a clinical trial of 110 stroke patients:

• Intranasal Semax (6,000 mcg/day for two 10-day courses) significantly increased plasma BDNF
• Patients showed improved motor performance and functional independence (Barthel index scores)
• Neurological recovery was meaningfully enhanced compared to controls

Semax reduces infarct volume in animal stroke models by attenuating the inflammatory cascade and protecting penumbral neurons — mechanisms that translate into better functional outcomes.

Depression and Anxiety

While Semax is primarily associated with cognitive enhancement rather than anxiolytic effects, research has documented:

• Antidepressant-like effects in animal models of chronic stress
• Normalization of anxious behavior in pharmacologically induced anxiety states
• Attenuation of behavioral stress responses without sedation

These effects appear most pronounced in animals whose stress systems have been disrupted, suggesting Semax may be particularly beneficial for stress-induced cognitive and mood impairment rather than baseline anxiety per se.

Alzheimer's Disease Research (2025)

A 2025 study published in PMC investigated Semax in an APP/PS1 mouse model of Alzheimer's disease. After a course of treatment, Semax significantly improved multiple behavioral parameters — open field exploration, novel object recognition, and Barnes maze performance. Crucially, treated mice performed at levels comparable to wild-type (non-Alzheimer's) animals, suggesting substantial therapeutic potential in neurodegeneration — though human clinical data in this area remains forthcoming.

Limitations

The evidence base, while impressive for a research peptide, still skews heavily toward Russian-language clinical research. Western replications are limited, most trials are short-duration, and long-term safety data remains sparse. Semax is not FDA-approved, and English-language peer review of its clinical trials is limited.

Semax Variants: Which Form Is Right for You?

Three main forms of Semax are available through research channels, each with different stability and potency profiles.

Standard Semax

The original formulation — the registered Russian pharmaceutical. Effective, well-studied, but has a relatively short half-life (2–4 hours in the CNS) due to enzymatic degradation at the N- and C-termini.

N-Acetyl Semax

An N-terminally acetylated version of Semax. The acetyl group at the N-terminus blocks aminopeptidase degradation, extending duration of action to approximately 6–8 hours. Considered more potent per mcg than standard Semax.

N-Acetyl Semax Amidate (NASA)

The most modified variant: N-terminal acetylation AND C-terminal amidation. This double protection against enzymatic degradation produces:

• Duration of action: 8–12 hours
• Enhanced bioavailability through nasal mucosa
• Greater potency — effective at lower doses (200–400 mcg vs 500–1,000 mcg for standard Semax)
• More consistent plasma levels

NASA is the preferred form for many experienced users due to fewer daily administrations required, though it carries the least formal clinical research compared to standard Semax.

Semax Dosing Protocols

Semax is administered intranasally. Oral administration is not viable due to rapid digestion of the peptide in the GI tract.

Standard Semax — Nasal Spray

Cognitive Enhancement Protocol:

• Dose: 250–1,000 mcg per administration
• Frequency: 1–3 times daily (morning and midday preferred; avoid evening)
• Cycle: 10–14 days on, 7–14 days off
• Starting point: Begin at 250–300 mcg to assess individual response

Stroke Recovery Protocol (Russian clinical standard):

• Dose: 2,000–6,000 mcg daily (divided into 3–4 doses at 3-4 hour intervals)
• Duration: 10 days on, 20 days off, then another 10-day course
• Note: High-dose stroke protocols should only be undertaken under physician supervision

N-Acetyl Semax Amidate — Nasal Spray

Protocol:

• Dose: 200–400 mcg once or twice daily
• Timing: Morning only, or morning + early afternoon (before 2 PM)
• Cycle: 10–14 days on, 7–14 days off

Timing Guidance

• Always dose in the morning or early afternoon — Semax's dopaminergic and stimulating properties can cause insomnia if taken in the evening
• Do not take on an empty stomach if GI sensitivity is a concern
• Allow 3–4 hours between doses for standard Semax; once or twice daily is sufficient for NASA

Semax vs. Selank: When to Use Each

Semax and Selank are the two most prominent Russian neuropeptides available as research compounds, and they complement each other precisely because they differ in meaningful ways.

The Semax + Selank Stack

Many experienced users combine Semax and Selank for a synergistic effect: Semax provides the cognitive edge and neural drive, while Selank smooths out any overstimulation or anxiety that Semax's dopaminergic effects might produce. The combination is often described as "calm, sharp focus" — a state difficult to achieve with either compound alone.

Example stacking protocol:

• Semax (standard): 300–500 mcg intranasal (morning)
• Selank: 200–300 mcg intranasal (same session or 20 minutes apart)

Side Effects and Safety

Semax has a strong safety record across decades of Russian clinical use, with formal toxicology studies finding no immune suppression, allergic reactions, embryotoxic effects, or mutagenic signals at therapeutic doses.

Commonly Reported Side Effects

• Nasal irritation or mild congestion (intranasal route)
• Transient metallic or unusual taste after administration
• Mild headache (typically early in use or at higher doses)
• Insomnia or sleep disturbance if dosed too late in the day
• Mild GI upset in some individuals

What Semax Does NOT Appear to Cause

• Adrenal stimulation or elevated cortisol (no hormonal activity)
• Physical dependence or withdrawal
• Sedation or cognitive impairment
• Significant blood pressure or cardiovascular changes at standard doses

Cautions

• Sleep sensitivity: Avoid evening dosing — this is the most consistent user-reported issue
• Stimulation sensitivity: Individuals sensitive to dopaminergic stimulants (e.g., those with anxiety disorders) may find Semax activating rather than calming; consider pairing with Selank
• Diabetics: Some reports suggest Semax may affect blood glucose regulation — monitor if applicable
• Pregnancy/breastfeeding: Insufficient safety data; avoid
• Drug interactions: Limited formal data; consult a physician if taking CNS-active medications

FDA and Regulatory Status

Semax is not FDA-approved for human use in the United States. It is classified as a research compound. The FDA has raised general concerns about immunogenicity risks for compounded peptides, which applies to Semax as with other peptide compounds sourced through US compounders.

Sourcing Semax in the United States

In the US, Semax is available through compounding pharmacies as a nasal spray or lyophilized powder. As with all compounded peptides, quality varies significantly between suppliers.

When sourcing compounded Semax:

• Prefer 503B outsourcing facilities operating under heightened FDA oversight
• Request a certificate of analysis (CoA) from an independent third-party lab confirming identity, purity (≥98%), and the absence of endotoxins
• Work with a physician experienced in peptide therapy — physician oversight improves both safety and protocol optimization
• Store per manufacturer instructions (typically refrigerated; protect from light)

Conclusion: Semax as a Cognitive Performance Tool

Semax occupies a unique position in the peptide landscape: it is simultaneously one of the most extensively researched nootropic peptides (with Russian clinical approvals and decades of use) and one of the most underappreciated in the Western research community. Its multi-mechanism action — BDNF/NGF upregulation, dopaminergic and serotonergic modulation, neuroprotection, gene expression regulation — produces effects that range from sharper daily cognition to meaningful neuroprotection in stroke and neurodegeneration.

For individuals seeking a research-backed cognitive enhancer with a clean safety record, Semax is one of the most compelling options available. Paired with Selank for anxious users, or used alone for pure cognitive performance, it represents the best of what synthetic neuropeptide research has produced.

As always: consult a qualified healthcare provider before use, source from reputable third-party-tested suppliers, and treat all human peptide use as exploratory given the limited Western clinical validation.

This article is for educational purposes only and does not constitute medical advice. Semax is not FDA-approved for human use in the United States.